{
    "nct_id": "NCT04553666",
    "official_title": "Reducing Frailty for Older Cancer Survivors Using Supplements (ReFOCUS): A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer",
    "inclusion_criteria": "1. Be age 65 or over.\n2. Be diagnosed with stage I-III Cancer.\n3. Have completed curative intent treatment ≤10 years prior to screening. (Patients on endocrine therapies are allowed to enroll.)\n4. Have a Fried's Frailty Score (FFS) of ≥ 2.\n5. Able to provide informed consent, or have consent given by patient-designated health care proxy per institutional policies and University of Rochester Cancer Control guidelines.\nHealthy volunteers allowed\nMust have minimum age of 65 Years",
    "exclusion_criteria": "Study subjects must not:\n\n1. Have chemotherapy planned for the during of the study.\n2. Have abnormal liver function tests (ALT, AST and bilirubin ≥3 times institutional upper limit of normal) per most recent available lab test (within 3 months of screening).\n3. Have uncontrolled or unmanaged liver disease.\n4. Consume more than 6 cups of green tea per day.\n5. Have known allergies to caffeine.\n6. Be diagnosed with a major psychiatric illness requiring hospitalization within the last year.\n7. Be diagnosed with dementia.\n8. Cannot provide informed consent due to lack of decision making capacity (as determined by the patient's oncologist) and has no patient-designated health care proxy per institutional policies and University of Rochester Cancer Control URCC guidelines.",
    "miscellaneous_criteria": ""
}